{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:08:56Z","timestamp":1780409336624,"version":"3.54.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"All Wales Lymphoma Panel"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.cgh.2019.09.031","type":"journal-article","created":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T20:16:55Z","timestamp":1570825015000},"page":"1785-1795.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Epstein-Barr Virus-Positive Mucocutaneous Ulcers Complicate Colitis Caused by Immune Checkpoint Regulator Therapy and Associate With Colon Perforation"],"prefix":"10.1016","volume":"18","author":[{"given":"Matthew R.","family":"Pugh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth D.","family":"Leopold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meleri","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam D.","family":"Christian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhys","family":"Hewett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharmaraj","family":"Durai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1140-5981","authenticated-orcid":false,"given":"John","family":"Wagstaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Dojcinov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2019.09.031_bib1","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cgh.2019.09.031_bib2","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.cllc.2017.02.001","article-title":"Immune checkpoint inhibitors for patients with advanced non-small-cell lung cancer: a systematic review","volume":"18","author":"Ellis","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cgh.2019.09.031_bib3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cgh.2019.09.031_bib4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11523-017-0495-4","article-title":"Immune checkpoint inhibitor-induced colitis: diagnosis and management","volume":"12","author":"Prieux-Klotz","year":"2017","journal-title":"Target Oncol"},{"key":"10.1016\/j.cgh.2019.09.031_bib5","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2019.09.031_bib6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2019.09.031_bib7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00428-017-2267-z","article-title":"Immune checkpoint inhibitor colitis: the flip side of the wonder drugs","volume":"472","author":"Assarzadegan","year":"2018","journal-title":"Virchows Arch"},{"key":"10.1016\/j.cgh.2019.09.031_bib8","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/CCO.0000000000000292","article-title":"Checkpoint inhibitors and gastrointestinal immune-related adverse events","volume":"28","author":"Pernot","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.cgh.2019.09.031_bib9","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/s41591-018-0238-9","article-title":"Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis","volume":"24","author":"Wang","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.cgh.2019.09.031_bib10","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ejca.2017.09.019","article-title":"Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis","volume":"86","author":"Franklin","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cgh.2019.09.031_bib11","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1128611","article-title":"Anti-TNF-refractory colitis after checkpoint inhibitor therapy: possible role of CMV-mediated immunopathogenesis","volume":"5","author":"Lankes","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.cgh.2019.09.031_bib12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.cgh.2019.09.031_bib13","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/pathogens7010028","article-title":"EBV-positive lymphoproliferations of B- T- and NK-cell derivation in non-immunocompromised hosts","volume":"7","author":"Dojcinov","year":"2018","journal-title":"Pathogens"},{"key":"10.1016\/j.cgh.2019.09.031_bib14","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/ecco-jcc\/jjv040","article-title":"Epstein-Barr virus in inflammatory bowel disease: the spectrum of intestinal lymphoproliferative disorders","volume":"9","author":"Nissen","year":"2015","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.09.031_bib15","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/PAS.0b013e3181cf8622","article-title":"EBV positive mucocutaneous ulcer: a study of 26 cases associated with various sources of immunosuppression","volume":"34","author":"Dojcinov","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.cgh.2019.09.031_bib16","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.cgh.2019.09.031_bib17","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.3748\/wjg.v21.i19.6072","article-title":"Epstein Barr virus-positive mucocutaneous ulcer of the colon associated Hodgkin lymphoma in Crohn's disease","volume":"21","author":"Moran","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.09.031_bib18","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.dld.2017.03.011","article-title":"Epstein-Barr virus-positive mucocutaneous ulcer in Crohn's disease: a condition to consider in immunosuppressed IBD patients","volume":"49","author":"Juan","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cgh.2019.09.031_bib19","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00384-019-03257-7","article-title":"Clinical and endoscopic complications of Epstein-Barr virus in inflammatory bowel disease: an illustrative case series","volume":"34","author":"Goetgebuer","year":"2019","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.cgh.2019.09.031_bib20","doi-asserted-by":"crossref","first-page":"4726","DOI":"10.1182\/blood-2010-12-323238","article-title":"Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma","volume":"117","author":"Dojcinov","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cgh.2019.09.031_bib21","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.cgh.2019.09.031_bib22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/PAS.0000000000001186","article-title":"The spectrum of EBV-positive mucocutaneous ulcer: a study of 9 cases","volume":"43","author":"Prieto-Torres","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.cgh.2019.09.031_bib23","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","article-title":"Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936","volume":"17","author":"van Dongen","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.cgh.2019.09.031_bib24","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1002\/ibd.22889","article-title":"Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease","volume":"18","author":"Sokol","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.09.031_bib25","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s12328-019-00952-4","article-title":"Immunomodulator-associated Epstein-Barr virus-positive mucocutaneous ulcer in a patient with refractory Crohn's disease","volume":"12","author":"Hamanaka","year":"2019","journal-title":"Clin J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.09.031_bib26","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1111\/imj.12287","article-title":"Two rare cases of Epstein-Barr virus-associated lymphoproliferative disorders in inflammatory bowel disease patients on thiopurines and other immunosuppressive medications","volume":"43","author":"Subramaniam","year":"2013","journal-title":"Intern Med J"},{"key":"10.1016\/j.cgh.2019.09.031_bib27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/pin.12745","article-title":"EBV-positive mucocutaneous ulcer arising in rheumatoid arthritis patients treated with methotrexate: single center series of nine cases","volume":"69","author":"Satou","year":"2019","journal-title":"Pathol Int"},{"key":"10.1016\/j.cgh.2019.09.031_bib28","first-page":"575","article-title":"Sigmoid diverticulosis: a risk factor for perforation of the sigmoid colon due to ipilimumab-associated enterocolitis?","volume":"13","author":"Hrgovic","year":"2015","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"key":"10.1016\/j.cgh.2019.09.031_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053745","article-title":"The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network","volume":"8","author":"Voskens","year":"2013","journal-title":"PLOS One"},{"key":"10.1016\/j.cgh.2019.09.031_bib30","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3748\/wjg.v23.i11.2023","article-title":"Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis","volume":"23","author":"Jain","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.09.031_bib31","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/ecco-jcc\/jjv239","article-title":"A\u00a0case of ipilimumab-induced anorectal fistula","volume":"10","author":"Balaphas","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.09.031_bib32","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2468-1253(16)30159-5","article-title":"Cytomegalovirus infection associated with inflammatory bowel disease","volume":"2","author":"Siegmund","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.09.031_bib33","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1097\/MIB.0000000000001095","article-title":"The association between CMV viremia or endoscopic features and histopathological characteristics of CMV colitis in patients with underlying ulcerative colitis","volume":"23","author":"Yang","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.09.031_bib34","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.clim.2018.07.012","article-title":"High frequencies of asymptomatic Epstein-Barr virus viremia in affected and unaffected individuals with CTLA4 mutations","volume":"195","author":"Hoshino","year":"2018","journal-title":"Clin Immunol"},{"key":"10.1016\/j.cgh.2019.09.031_bib35","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.3389\/fimmu.2018.02012","article-title":"Increased risk for malignancies in 131 affected CTLA4 mutation carriers","volume":"9","author":"Egg","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.cgh.2019.09.031_bib36","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122092","article-title":"T\u00a0cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma","volume":"3","author":"Hopkins","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.cgh.2019.09.031_bib37","doi-asserted-by":"crossref","DOI":"10.4161\/onci.29244","article-title":"Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes","volume":"3","author":"Robert","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.cgh.2019.09.031_bib38","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40425-015-0070-4","article-title":"Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma","volume":"3","author":"Postow","year":"2015","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/j.cgh.2019.09.031_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005642","article-title":"PD-1\/CTLA-4 blockade inhibits Epstein-Barr virus-induced lymphoma growth in a cord blood humanized-mouse model","volume":"12","author":"Ma","year":"2016","journal-title":"PLOS Pathogens"},{"key":"10.1016\/j.cgh.2019.09.031_bib40","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/s41467-017-01018-0","article-title":"Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers","volume":"8","author":"Ock","year":"2017","journal-title":"Nature Communications"},{"key":"10.1016\/j.cgh.2019.09.031_bib41","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1158\/0008-5472.CAN-16-2324","article-title":"Immune toxicities elicted by CTLA-4 blockade in cancer patients are associated with early diversification of the T-cell repertoire","volume":"77","author":"Oh","year":"2017","journal-title":"Cancer Res"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356519310808?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356519310808?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:31:57Z","timestamp":1761543117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356519310808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S1542356519310808"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2019.09.031","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epstein-Barr Virus-Positive Mucocutaneous Ulcers Complicate Colitis Caused by Immune Checkpoint Regulator Therapy and Associate With Colon Perforation","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2019.09.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the AGA Institute","name":"copyright","label":"Copyright"}]}}